On May 16, 2016, Xtant Medical Holdings, Inc. announced a licensing agreement with Sites Medical LLC. Together, the two medtech leaders are bolstering Sites Medical’s OsteoSyn Ti technology, a premium porous titanium scaffold. The product will be available to both national and international markets.
Xtant + Sites Medical Team up for Titanium Scaffold
2 min read Premium comments
Secondary
Xtant is based in Belgrade, Montana and is a developer and manufacturer for renowned regenerative medical products. Specializing in devises for orthopedic and neurological surgeons, Xtant is well-known for implants, spinal disease instruments, tissue graft products for orthopedic disorders, and biologics aiding in foot, ankle and cranial surgeries.
Sites Medical in Fort Wayne, Indiana, played a critical role in healthcare reimbursement approaches, focusing exclusively on “Value-Driven Innovation” within orthopedics. Known for their impressive lineup or orthopedic implant devices and manufacturing prowess, Sites Medical prioritizes improving outcomes while simultaneously reducing costs.
Xtant CEO Carl O’Connell said, “We are very excited to work with Sites Medical. As market dynamics shift towards emerging titanium technologies, Sites Medical’s OsteoSync Ti technology places us firmly at the forefront of this trend.”
The Sites Medical leadership team is also excited about the partnership. President and CEO Greg Stalcup said, “We are thrilled to be partnering with Xtant Medical, a company with a rich history of innovation in the spine field. We look forward to working with the Xtant team to combine our respective technologies to deliver a new generation of high performance, high value products to the market.”
What is OsteoSync Ti?
The proprietary technology was crafted to tackle the needs of contemporary patients from both a clinical and economic perspective. The implant features incredible stability with a high friction co-efficiency. With open pore design and micro-texturing, it’s designed to encourage optimal bone ingrowth. In preclinical tests, bone attachment strength with OsteoSync Ti technology was almost twice as strong compared to titanium plasma sprays and seven times more effective than PEEK material in a five-week follow-up analysis.
Ultimately, these performance differences suggest clinical outcomes, particularly for those undergoing spinal fusion surgeries. Additionally, the technology was created to minimize “abrasion debris” that’s relatively common in implant insertion—offering more safeguards for patients.
Although OsteoSync Ti technology has been shown to perform phenomenally better, and safer, than its competitors, it’s also surprisingly economical. Both Xtant and Sites Medical agree it’s a breath of fresh air in today’s often costly healthcare industry.
Money Matters
Xtant’s second quarter metrics suggest the US market makeup that may utilize OsteoSync Ti tech hovers around $2.5 billion. The five-year compound annual growth rate (CAGR) is near 4.75%. The first Xtant Medical products featuring the technology will be showcased at the North American Spine Society annual meeting October 25 – 28 in Orlando, Florida. Registration is open now.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.